| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
The present study investigated the radioprotective effect of the strong mitogenic activity of FGF1 on the radiation-induced intestinal damage, and the radiosensitivity and metastatic capabilities of the murine tumorigenic endothelial cell line ISOS-1. As a result, strong FGF1 signaling exerted not only radioprotective effects in the intestine, but also the enhanced radiosensitivity of ISOS-1 cells and inhibitory effects on its metastatic capabilities. In addition, the comparative study on the radiosensitivity of human hemangiosarcoma cell line ISO-HAS and human lymphangiosarcoma cell line MO-LAS was also performed. Both cell lines had almost the same radiosensitivity. These findings suggest that strong FGF1 signaling is useful for not only attenuating the adverse effects of radiotherapy against angiosarcoma, but also inhibiting the malignancy of angiosarcoma.
|
